EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Grape King Bio's enterprise value is NT$18,079 Mil.
Grape King Bio's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was NT$3,135 Mil. Therefore, Grape King Bio's EV-to-EBITDA for today is 5.77.
The historical rank and industry rank for Grape King Bio's EV-to-EBITDA or its related term are showing as below:
TPE:1707'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.32 Med: 9.46 Max: 16.87
Current: 5.77
During the past 13 years, the highest EV-to-EBITDA of Grape King Bio was 16.87. The lowest was 5.32. And the median was 9.46.
TPE:1707's EV-to-EBITDA is ranked better than 85.31% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.98
vs TPE:1707: 5.77
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Grape King Bio EV-to-EBITDA Historical Data
The historical data trend for Grape King Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Grape King Bio's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Grape King Bio's EV-to-EBITDA falls into.
Grape King Bio's current Enterprise Value is NT$18,079 Mil.
Grape King Bio's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3,135 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grape King Bio (TPE:1707) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Grape King Bio's PE Ratio (TTM) for today is calculated as:
Grape King Bio's share price for today is NT$134.50.
Grape King Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$9.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Grape King Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicine, liquid tonic, drink, and healthy food. The company has three segments: MLM (Multi-Level Marketing) is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TPE:1707 has been successfully added to your 